University of Pennsylvania Medical Center, Department of Pharmacology and Program in Targeted Therapeutics of Institute of Translational Medicine and Therapeutics, IFEM, One John Morgan Building, 3620 Hamilton Walk, Philadelphia, PA 19104-6068, USA.
Expert Opin Drug Deliv. 2010 Apr;7(4):403-27. doi: 10.1517/17425241003610633.
Vascular delivery of several classes of therapeutic agents may benefit from carriage by red blood cells (RBC), for example, drugs that require delivery into phagocytic cells and those that must act within the vascular lumen. The fact that several protocols of infusion of RBC-encapsulated drugs are now being explored in patients illustrates a high biomedical importance for the field. AREAS COVERED BY THIS REVIEW: Two strategies for RBC drug delivery are discussed: encapsulation into isolated RBC ex vivo followed by infusion in compatible recipients and coupling therapeutics to the surface of RBC. Studies of pharmacokinetics and effects in animal models and in human studies of diverse therapeutic enzymes, antibiotics and other drugs encapsulated in RBC are described and critically analyzed. Coupling to RBC surface of compounds regulating immune response and complement, affinity ligands, polyethylene glycol alleviating immune response to donor RBC and fibrinolytic plasminogen activators are described. Also described is a new, translation-prone approach for RBC drug delivery by injection of therapeutics conjugated with fragments of antibodies providing safe anchoring of cargoes to circulating RBC, without need for ex vivo modification and infusion of RBC.
Readers will gain historical perspective, current status, challenges and perspectives of medical applications of RBC for drug delivery.
RBC represent naturally designed carriers for intravascular drug delivery, characterized by unique longevity in the bloodstream, biocompatibility and safe physiological mechanisms for metabolism. New approaches for encapsulating drugs into RBC and coupling to RBC surface provide promising avenues for safe and widely useful improvement of drug delivery in the vascular system.
几种治疗药物的血管输送可能受益于红细胞(RBC)的携带,例如需要递送到吞噬细胞内的药物和必须在血管腔内起作用的药物。目前正在探索用 RBC 包裹的药物输注几种方案,这一事实说明了该领域具有很高的生物医学重要性。
讨论了两种 RBC 药物输送策略:将药物包封到分离的 RBC 中,然后在相容的受者中输注,以及将治疗剂偶联到 RBC 表面。描述并批判性分析了在动物模型和不同治疗性酶、抗生素和其他包裹在 RBC 中的药物的人体研究中进行的药代动力学和效应研究。还描述了用于调节免疫反应和补体的化合物、亲和配体、减轻对供体 RBC 免疫反应的聚乙二醇和纤维蛋白溶酶原激活剂与 RBC 表面偶联的方法。还描述了一种新的、易于翻译的 RBC 药物输送方法,通过注射与抗体片段偶联的治疗剂,为循环 RBC 上的货物提供安全的锚定,而无需进行体外修饰和 RBC 输注。
读者将获得 RBC 用于药物输送的医学应用的历史背景、现状、挑战和展望。
RBC 代表用于血管内药物输送的天然设计载体,其特点是在血液中的独特长寿性、生物相容性和安全的代谢生理机制。将药物包封到 RBC 中并偶联到 RBC 表面的新方法为安全且广泛有用地改善血管系统中的药物输送提供了有希望的途径。